BC Innovations | Jul 17, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Phospholipase A2 group V (PLA2G5); PLA2G2E Mouse studies suggest stabilizing PLA2G5 or inhibiting PLA2G2E could help treat or prevent metabolic diseases including obesity....
Items per page:
1 - 1 of 1